Continuing fingolimod after development of macular edema: A case report
نویسندگان
چکیده
Fingolimod is the first effective oral agent in widespread use for relapsing-remitting multiple sclerosis (MS), but it can cause macular edema (ME) as an uncommon complication.MEmay be mild and asymptomatic, but it can also produce visual impairment. The mechanism of fingolimod-associated ME (FAME) is thought to be through sphingosine-1-phosphate receptor antagonism, affecting endothelial integrity and increasing the risk of microvascular leaks. Analysis of phase 2 and 3 fingolimod studies found 19 cases of ME out of 2,615 patients (0.7%). Thirteen had onset within 4 months of fingolimod commencement, 4 had onset between 4 and 12months, and 2 had onset after 12 months. Fingolimod was ceased in all cases, with complete resolution of ME in 16 and partial resolution in the remainder. Eleven required treatment with topical anti-inflammatory drugs. Risk factors for FAME include previous uveitis and diabetes. Themost sensitive technique for detectingME is optical coherence tomography (OCT). Treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, vascular endothelial growth factor antagonists, laser photocoagulation, and vitreoretinal surgery. However, all have side effects, including delayed healing, increased bleeding and infection risk, and elevated intraocular pressure.
منابع مشابه
Evaluation of the Incidence of Macular Edema in Patients with Multiple Sclerosis Treated with Fingolimod
Purpose: To determine the incidence of macular edema in patients with MS treated with 0.5 mg Fingolimod. Methods: In this prospective descriptive-analytic study a total of 115 patients were enrolled. Patients underwent an ophthalmologic examination before starting the treatment. In the fourth month after starting the treatment for each patient, regardless of whether or not being marked, the oph...
متن کاملAcute onset of fingolimod-associated macular edema
Purpose Fingolimod is among the first oral disease-modifying agents for the treatment of relapsing-remitting multiple sclerosis (MS). Despite its favorable safety profile, fingolimod may cause macular edema, a significant adverse event, which occurs within the first 4 months of therapy. Macular edema usually resolves upon discontinuation of fingolimod; however, the time required for resolution ...
متن کاملEarly Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis
We report a case of fingolimod-associated bilateral cystoid macular oedema in a patient with multiple sclerosis (MS). A 34-year-old female, diagnosed with MS at age of 30, developed bilateral blurred vision 5 days after initiation of fingolimod. She was misdiagnosed as optic neuritis initially and fingolimod was only discontinued 3 weeks after onset of her visual symptoms when OCT showed promin...
متن کاملRetinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report
BACKGROUND Fingolimod is the first oral agent used for treatment of relapsing-remitting multiple sclerosis. Macular edema, but not retinal hemorrhage, is a well-known adverse effect of fingolimod treatment. To the best of our knowledge, this is the first case report of extensive retinal hemorrhages following fingolimod treatment. CASE PRESENTATION A 31-year-old male with relapsing-remitting m...
متن کاملImprovement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis
INTRODUCTION Generally, fingolimod administration is simply discontinued when fingolimod-associated macular edema (ME) appears, and the majority of cases are said to recover spontaneously. However, to the best of our knowledge, this is the 1st report regarding improvement of ME without discontinuation of fingolimod administration. CASE PRESENTATION The patient was a 66-year-old woman with rel...
متن کامل